{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:51:34Z","timestamp":1773118294454,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.avsg.2025.07.029","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T23:18:07Z","timestamp":1753399087000},"page":"298-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Early Economic Evaluation of Single Versus Dual Antiplatelet Therapy After Endovascular Revascularization for Peripheral Artery Disease"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4393-3572","authenticated-orcid":false,"given":"Manon I.","family":"Generaal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilien C.J.","family":"Wegerif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fda\u015f","family":"\u00dcnl\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert J.","family":"de Borst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert W.J.","family":"Frederix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam P.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2025.07.029_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2796.2002.00947.x","article-title":"Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy","volume":"251","author":"Hiatt","year":"2002","journal-title":"J Intern Med"},{"key":"10.1016\/j.avsg.2025.07.029_bib2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"Editor's choice - European society for vascular surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases","volume":"65","author":"Twine","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2025.07.029_bib4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40265-022-01756-6","article-title":"Antithrombotic therapy for symptomatic peripheral arterial disease: a systematic review and network meta-analysis","volume":"82","author":"Willems","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.avsg.2025.07.029_bib5","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.2174\/1381612825666190101100832","article-title":"Rivaroxaban versus clopidogrel for peripheral artery disease: a clinico-economic approach of the COMPASS trial","volume":"24","author":"Tsilimigras","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.avsg.2025.07.029_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11593380-000000000-00000","article-title":"Early assessment of medical technologies to inform product development and market access","volume":"9","author":"Ijzerman","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.avsg.2025.07.029_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187477","article-title":"Update of the Dutch manual for costing studies in health care","volume":"12","author":"Kanters","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.avsg.2025.07.029_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.avsg.2025.07.029_bib9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0272989X18754513","article-title":"Microsimulation modeling for health decision sciences using R: a tutorial","volume":"38","author":"Krijkamp","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.avsg.2025.07.029_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2025.07.029_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2025.07.029_bib12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"Jama"},{"key":"10.1016\/j.avsg.2025.07.029_bib13","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2025.07.029_bib15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2025.07.029_bib16","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2025.07.029_bib17","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1177\/2047487320913380","article-title":"Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study","volume":"27","author":"Petersohn","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.avsg.2025.07.029_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1526602819833646","article-title":"A comparative cost-effectiveness analysis of percutaneous transluminal angioplasty with optional stenting and femoropopliteal bypass surgery for medium-length TASC II B and C femoropopliteal lesions","volume":"26","author":"Vossen","year":"2019","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2025.07.029_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12471-013-0386-y","article-title":"Treatment costs of acute myocardial infarction in The Netherlands","volume":"21","author":"Soekhlal","year":"2013","journal-title":"Neth Heart J"},{"key":"10.1016\/j.avsg.2025.07.029_bib20","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/13696998.2021.1997024","article-title":"Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in The Netherlands","volume":"24","author":"Spoorendonk","year":"2021","journal-title":"J Med Econ"},{"key":"10.1016\/j.avsg.2025.07.029_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008220","article-title":"The burden of stroke in The Netherlands: estimating quality of life and costs for 1 year poststroke","volume":"5","author":"van Eeden","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.avsg.2025.07.029_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064445","article-title":"Drivers of healthcare costs in patients with ischaemic stroke: a hospital-based retrospective cohort study","volume":"13","author":"Mensing","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.avsg.2025.07.029_bib23","series-title":"Kosteneffectiviteit in de praktijk","year":"2015"},{"key":"10.1016\/j.avsg.2025.07.029_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12955-020-01407-y","article-title":"Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review","volume":"18","author":"Betts","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.avsg.2025.07.029_bib25","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.jcin.2016.08.036","article-title":"Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial","volume":"9","author":"Salisbury","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2025.07.029_bib26","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Making"},{"key":"10.1016\/j.avsg.2025.07.029_bib27","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3111\/13696998.2016.1154567","article-title":"Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US","volume":"19","author":"Bruhn","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.avsg.2025.07.029_bib28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1262-3636(07)70154-4","article-title":"Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments","volume":"30","author":"Redekop","year":"2004","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.avsg.2025.07.029_bib29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.14610","article-title":"Decrements in health-related quality of life associated with adverse events in people with diabetes","volume":"24","author":"Keng","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.avsg.2025.07.029_bib30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jval.2016.04.015","article-title":"The international decision support initiative reference case for economic evaluation: an aid to thought","volume":"19","author":"Wilkinson","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.avsg.2025.07.029_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","article-title":"Value of information analysis for research decisions\u2014an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force","volume":"23","author":"Fenwick","year":"2020","journal-title":"Value in Health"},{"key":"10.1016\/j.avsg.2025.07.029_bib32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2025.07.029_bib33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjmed.2004.01.014","article-title":"Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis","volume":"116","author":"Schleinitz","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.avsg.2025.07.029_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/11535520-000000000-00000","article-title":"Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations","volume":"8","author":"Logman","year":"2010","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.avsg.2025.07.029_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/13696998.2020.1724119","article-title":"Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China","volume":"23","author":"Lin","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.avsg.2025.07.029_bib36","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2025.07.029_bib37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1524-4733.2009.00529.x","article-title":"Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial","volume":"12","author":"Chen","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.avsg.2025.07.029_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1478-7547-8-21","article-title":"Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach","volume":"8","author":"Baeten","year":"2010","journal-title":"Cost Eff Resour Alloc"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509625005060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509625005060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:29:12Z","timestamp":1773073752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509625005060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S0890509625005060"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2025.07.029","relation":{},"ISSN":["0890-5096"],"issn-type":[{"value":"0890-5096","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Economic Evaluation of Single Versus Dual Antiplatelet Therapy After Endovascular Revascularization for Peripheral Artery Disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2025.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}